Valbiotis (XPAR:ALVAL) Total Equity: €6.96 Mil (As of Dec. 2025)


XPAR:ALVAL Valbiotis SA XPAR:ALVAL
55 GF Score
Price €0.75
GF Value €1.49
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Valbiotis Total Equity?

Valbiotis XPAR:ALVAL -7.22% 55 Total Equity is €6.96 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVAL with a GF Score™ of 55/100 and a GF Value™ of €1.49 (Possible Value Trap). The stock has 6 warning signs investors should review.

Valbiotis's total equity for the quarter that ended in Dec. 2025 was €6.96 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Valbiotis Total Equity Historical Data

* Premium members only.

The historical data trend for Valbiotis's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valbiotis Total Equity Chart

Valbiotis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.30 13.36 19.60 10.37 6.96

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.60 16.84 10.37 11.75 6.96
XPAR:ALVAL
55GF Score
Valbiotis SA XPAR:ALVAL
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valbiotis Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Valbiotis's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=14.388-7.427
=6.96

Valbiotis's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=14.388-7.427
=6.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €6.96 Mil mean?
Valbiotis (XPAR:ALVAL) has a Total Equity of €6.96 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Valbiotis and its competitors.
Is Valbiotis' Total Equity too high?
Valbiotis' current Total Equity is €6.96 Mil. Overall, Valbiotis has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' Total Equity compare to KHC and GIS?
Valbiotis' Total Equity of €6.96 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Consumer Packaged Goods company?
A good Total Equity depends on the Consumer Packaged Goods industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Valbiotis and its competitors. Valbiotis's current Total Equity is €6.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.49, compared to a current price of €0.75 — trading 50% below its estimated fair value. The current Total Equity is €6.96 Mil. Valbiotis' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current Total Equity is €6.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?

Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued. The current stock price of €0.75 is trading 50% below its estimated GF Value™ of €1.49. GuruFocus considers Valbiotis to be Possible Value Trap.

Key valuation signals for XPAR:ALVAL:

  • Total Equity: €6.96 Mil
  • GF Value™: €1.49 vs. price of €0.75 (50% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valbiotis Business Description

Other Exchanges 8JD:Germany
Address 12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
55GF Score

Get the complete analysis for XPAR:ALVAL

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price
€1.49
GF Value